Overall rank by patents
#40,343
Across all tracked assignees
USPTO PatentsView assignee record - 6 granted patents across 2 technology areas, active 2015–2022. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61B (DIAGNOSIS; SURGERY; IDENTIFICATION).
The verdict
Galil holds 6 US patents across 2 technology areas, rank #40,343 of 50,000 tracked assignees.
Galil Medical Inc. has been granted 6 US utility patents between 2015 and 2022, placing Galil Medical Inc. at rank #40,343 across all assignees tracked by PlainPatent. This portfolio spans 2 distinct Cooperative Patent Classification (CPC) subclasses, averaging 10.8 claims per patent with primary concentration in A61B (DIAGNOSIS; SURGERY; IDENTIFICATION). As a US Corporation, Galil Medical Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Galil sits between GABA International Holding Gmbh (6 patents, rank #40,339) and GAME Freak Inc. (6 patents, rank #40,347) - the closest US assignees by grant volume. The composite Innovation Score of 22.7/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 4 grants, compared with 2 in the 2015–2019 window, a +100% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Galil Medical Inc.'s 10.8 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while specialization in 2 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Galil Medical Inc. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
GABA International Holding GmbH
6 patents
GABOSS INTERNATIONAL LIMITED
6 patents
GALATA CHEMICALS LLC
6 patents
GALAXY BIOTECH, LLC
6 patents
GALLANT MICRO. MACHINING CO., LTD.
6 patents
GALMED RESEARCH AND DEVELOPMENT LTD
6 patents
GALOMB, INC.
6 patents
GAME FREAK INC.
6 patents
GALIL MEDICAL INC.
6 patents
What this shows Galil holds 6 patents at rank #40,343, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #40,343 in granted patent volume.
Other assignees with the most granted patents in Galil's primary technology class.
Galil's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
23 Top 89% higher than 11% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 1 | 16.7% |
| 2019 | 1 | 16.7% |
| 2021 | 2 | 33.3% |
| 2022 | 2 | 33.3% |
Top 2 of 2 technology areas
Overall rank by patents
#40,343
Across all tracked assignees
22.7 out of 100
How to use this portfolio
Galil's 6 grants land it in the top 89% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.